特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
465219

サンドホフ病(ジャッケウィッツ-ピルツ病):パイプライン製品の分析

Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Pipeline Review, H2 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 45 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.70円
サンドホフ病(ジャッケウィッツ-ピルツ病):パイプライン製品の分析
出版日: 2020年08月31日
発行: Global Markets Direct
ページ情報: 英文 45 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

サンドホフ病(ジャッケウィッツ‐ピルツ病)は、先天性の脂質蓄積障害であり、脳および脊髄の神経細胞(ニューロン)を破壊する進行性の疾患です。ベータ-ヘキソサミニダーゼ酵素の不足が原因で起こります。症状は、神経系機能の低下が進み、筋肉を動かしたり、行動を起こすのに支障が出たり、音に対する驚愕反応が増したり、初期の失明や発作、痙攣および間代性筋痙攣などが起こります。治療は痙攣を抑えるための鎮痙剤を用います。

当レポートでは、サンドホフ病(ジャッケウィッツ‐ピルツ病)の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

サンドホフ病(ジャッケウィッツ‐ピルツ病);概要

治療薬の開発

  • パイプライン製品;概要
  • 企業別のパイプライン製品
  • 大学/研究機関別のパイプライン製品
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Bioasis Technologies Inc
  • Nuo Therapeutics Inc

薬剤プロファイル

  • ALD-601
  • CCP-010
  • DUOC-01
  • MTf-HEXB
  • MTfp-HEXB
  • OT-1001

休止中のプロジェクト

付録

図表

図表

List of Tables

List of Tables

  • Number of Products under Development for Sandhoff Disease (Jatzkewitz-Pilz Syndrome), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Pipeline by Axovant Gene Therapies Ltd, H2 2020
  • Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Pipeline by Genzyme Corp, H2 2020
  • Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Pipeline by IntraBio Ltd, H2 2020
  • Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Pipeline by Orphi Therapeutics Inc, H2 2020
  • Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Pipeline by Polaryx Therapeutics Inc, H2 2020
  • Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Pipeline by Taysha Gene Therapies, H2 2020
  • Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Dormant Projects, H2 2020

List of Figures

List of Figures

  • Number of Products under Development for Sandhoff Disease (Jatzkewitz-Pilz Syndrome), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Targets, H2 2020
  • Number of Products by Stage and Targets, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
目次
Product Code: GMDHC12430IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Pipeline Review, H2 2020, provides an overview of the Sandhoff Disease (Jatzkewitz-Pilz Syndrome) (Genetic Disorders) pipeline landscape.

Sandhoff disease is an inherited lipid storage disorder that progressively destroys nerve cells (neurons) in the brain and spinal cord. It is caused by a deficiency of the enzyme beta-hexosaminidase. Symptoms include progressive nervous system deterioration, problems initiating and controlling muscles and movement, increased startle reaction to sound, early blindness, seizures, spasticity, and myoclonus. Treatment includes anticonvulsants to control seizures.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Sandhoff Disease (Jatzkewitz-Pilz Syndrome) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sandhoff Disease (Jatzkewitz-Pilz Syndrome) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sandhoff Disease (Jatzkewitz-Pilz Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 4 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Sandhoff Disease (Jatzkewitz-Pilz Syndrome) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sandhoff Disease (Jatzkewitz-Pilz Syndrome) (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Sandhoff Disease (Jatzkewitz-Pilz Syndrome) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sandhoff Disease (Jatzkewitz-Pilz Syndrome) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sandhoff Disease (Jatzkewitz-Pilz Syndrome) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sandhoff Disease (Jatzkewitz-Pilz Syndrome) (Genetic Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sandhoff Disease (Jatzkewitz-Pilz Syndrome) (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sandhoff Disease (Jatzkewitz-Pilz Syndrome) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Overview
  • Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Companies Involved in Therapeutics Development
  • Axovant Gene Therapies Ltd
  • Genzyme Corp
  • IntraBio Ltd
  • Orphi Therapeutics Inc
  • Polaryx Therapeutics Inc
  • Taysha Gene Therapies
  • Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Drug Profiles
  • acetylleucine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AXO-AAV-GM2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Dormant Projects
  • Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Product Development Milestones
  • Featured News & Press Releases
  • Mar 25, 2020: IntraBio Fast Track Designation for GM2 Gangliosidosis
  • Feb 11, 2019: ntraBio investigational new drug application approved by the FDA for the treatment of tay-sachs and sandhoff disease
  • Dec 12, 2018: IntraBio receives Tay-Sachs and Sandhoff Rare pediatric disease designation from the FDA
  • Nov 19, 2018: IntraBio receives Tay-Sachs and Sandhoff European Orphan Drug Designation
  • Oct 01, 2018: Intrabio receives FDA rare pediatric disease designation for ib1000 for GM2 Gangliosidoses
  • Mar 28, 2018: Intrabio receives FDA orphan drug designation for ib1000 for GM2 Gangliosidoses
  • Oct 30, 2017: Intrabio receives EMA orphan medicinal drug designation for IB1000s for GM2 Gangliosidoses
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.